StemCell Therapy

By Medicine Hat News on March 3, 2020.

The province will cover the cost of another drug for Albertans with cystic fibrosis.

Effective March 1 the drug kalydeco is part of the governments drug plan.

Since 2014 kalydeco has been available to patients more than six years old who had cystic fibrosis and one specific genetic mutation. The coverage is now expanded to include an additional eight genetic mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N and S549R.

Patients over 18 with an R117H mutation in the CFTR gene will also be covered for this medication.

Cystic fibrosis is a genetic disease affecting the digestive system and lungs primarily. The severity of the disease differs from person to person and it is often fatal.

The government said the pan-Canadian Pharmaceutical Alliance was able to negotiate a pricing agreement with the manufacturer of this prescription drug that made expanded coverage possible.

You must be logged in to post a comment.

Excerpt from:
Alberta to cover another cystic fibrosis medication - Medicine Hat News

This entry was posted on March 7, 2020 at 2:48 pm and is filed under Genetic medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |